CAMBRIDGE, Mass.--(BUSINESS WIRE)--Boston Pharmaceuticals today announced the appointment of Ian Sanderson as Chief Financial Officer. As a member of Boston Pharmaceuticals’ senior leadership team, Mr. Sanderson will be involved with the Company’s evaluation, acquisition, and development of differentiated clinical programs for the Boston Pharmaceuticals drug portfolio.
Robert Armstrong, CEO and co-founder of Boston Pharmaceuticals remarked, “Ian has extensive expertise in the evaluation and financing of clinical development programs, and brings to Boston Pharmaceuticals critical perspectives to our analyses of potential new product opportunities. We welcome him to our leadership team and look forward to his transaction and strategic insights as we build our portfolio of development programs through mutually advantageous collaborations with our partner companies.”
“The Boston Pharmaceuticals model is driven by highly efficient program evaluation, clinical development and capital deployment,” said Mr. Sanderson. “I look forward to contributing my analytical and transactional experience to help the Boston Pharmaceuticals team create a deep pipeline of differentiated clinical programs and bring important new medicines to patients.”
Mr. Sanderson joins Boston Pharmaceuticals from Catabasis Pharmaceuticals, where he was Chief Financial Officer. While at Catabasis, Mr. Sanderson oversaw operations and led the company’s re-positioning and successful IPO in 2015. Prior to joining Catabasis, Mr. Sanderson was a senior advisor with JSB Partners, advising life sciences companies on corporate finance, M&A and business development transactions. Before JSB Partners, Mr. Sanderson spent 20 years with Cowen and Company, most recently as a Managing Director and Senior Pharmaceuticals Analyst, leading Cowen’s emerging and specialty pharmaceuticals research team. During his career at Cowen, Mr. Sanderson was named to several Institutional Investor Analyst All Star teams for his coverage of the specialty pharmaceuticals sector, and helped build one of the top-ranked healthcare research teams on Wall Street. Prior to his pharmaceuticals research analyst career, Mr. Sanderson was a health care investment banker with Cowen and Houlihan Lokey. He began his healthcare career in the finance group of U.S. Surgical Corporation (now Medtronic). Mr. Sanderson earned an MBA in finance from the Wharton School and a BA in Political Economy from Williams College.
About Boston Pharmaceuticals
Boston Pharmaceuticals was launched as a new pharmaceutical company model, providing a bridge to value realization for early stage clinical development programs. By offering strategic partnership options to biotech and pharmaceutical companies, our goal is to enable differentiated, under-resourced therapeutics to be developed and made available to patients with unmet medical needs. We focus primarily on clinical development from IND through Phase 2 clinical proof-of-concept (PoC). Our team leverages an average of over 20 years of drug development experience and a broad network of external resources to design and execute highly efficient, definitive clinical PoC programs, enabling our partners to advance into pivotal trials with a high probability of success. We are actively investing $600 million of committed capital to build a diversified portfolio. We are funded by Gurnet Point Capital, a $2 billion healthcare private equity fund.